(₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
---|---|---|---|---|---|
Total Income | 169.34 | 149.51 | 157.69 | 13.3% | 7.4% |
Total Expenses | 133.95 | 127.30 | 128.21 | 5.2% | 4.5% |
Profit Before Tax | 35.39 | 22.22 | 29.48 | 59.3% | 20.0% |
Tax | 7.71 | 3.62 | 5.81 | 113.0% | 32.7% |
Profit After Tax | 27.68 | 18.60 | 23.67 | 48.8% | 16.9% |
Earnings Per Share | 13.80 | 9.30 | 11.80 | 48.4% | 16.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Lincoln Pharmaceuticals Ltd is a well-established entity within the pharmaceutical industry, primarily engaged in the manufacture and distribution of pharmaceutical products. The company is known for its extensive range of formulations, which include tablets, capsules, injectables, and novel drug delivery systems. Its core business revolves around the development and marketing of generic and branded pharmaceutical products. As of the most recent updates, Lincoln Pharmaceuticals has been focusing on expanding its market reach and enhancing its product portfolio through strategic investments and partnerships. However, specific major developments in recent quarters are not available within the provided data.
In the first quarter of the fiscal year 2026 (Q1FY26), Lincoln Pharmaceuticals Ltd reported a total income of ₹169.34 crores. This represents a quarter-over-quarter (QoQ) increase of 13.3% compared to the previous quarter (Q4FY25), where total income stood at ₹149.51 crores. Year-over-year (YoY), there was a growth of 7.4% compared to the same quarter in the previous year (Q1FY25), with total income recorded at ₹157.69 crores. This upward trajectory in revenue generation indicates robust performance over both the QoQ and YoY periods, reflecting potential growth in sales volume or pricing adjustments.
The company experienced considerable improvements in its profitability metrics as of Q1FY26. Profit Before Tax (PBT) reached ₹35.39 crores, marking a significant QoQ increase of 59.3% from ₹22.22 crores in Q4FY25. On a YoY basis, PBT rose by 20.0% from ₹29.48 crores in Q1FY25. Correspondingly, Profit After Tax (PAT) for Q1FY26 was ₹27.68 crores, which is a 48.8% increase QoQ from ₹18.60 crores in Q4FY25, and a 16.9% increase YoY from ₹23.67 crores in Q1FY25. The company's earnings per share (EPS) also increased to ₹13.80 in Q1FY26 from ₹9.30 in Q4FY25 and ₹11.80 in Q1FY25, reflecting similar trends in profitability improvements.
The total expenses for Lincoln Pharmaceuticals Ltd were reported at ₹133.95 crores in Q1FY26, showing a QoQ increase of 5.2% from ₹127.30 crores in Q4FY25 and a YoY increase of 4.5% from ₹128.21 crores in Q1FY25. The tax expense for Q1FY26 was ₹7.71 crores, a notable increase of 113.0% QoQ from ₹3.62 crores in Q4FY25, and a 32.7% increase YoY from ₹5.81 crores in Q1FY25. These figures suggest an upward trend in operational expenditure and tax liabilities, which could be indicative of expanded operational activity or changes in tax policy. The company's financial performance metrics highlight the cost management and operational scale relative to its revenue growth.
Lincoln Pharmaceuticals Ltd announced its Q1 FY 2025-26 results on 8 August, 2025.
Lincoln Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Lincoln Pharmaceuticals Ltd Q1 FY 2025-26 results include:
Lincoln Pharmaceuticals Ltd reported a net profit of ₹27.68 crore in Q1 FY 2025-26, reflecting a 16.9% year-over-year growth.
Lincoln Pharmaceuticals Ltd posted a revenue of ₹169.34 crore in Q1 FY 2025-26.